SEP invested in Arakis, a speciality pharmaceutical company with a focus on oncology and inflammatory diseases, in 2004.
The company, which focused on low risk, rapid development opportunities, was acquired for £107.5 million by Sosei, a Japanese quoted company, in 2005.